COMP <GO>
AGEN vs ABBV // REVENUE GROWTH (YOY)
Agenus Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: AGEN 2
— ABBV 8
▲ REVENUE GROWTH (YOY) LEADER: AGEN
LAST: $7.09 (-0.56%) • MKT CAP: $320.2M
revenue-growth
10.40%
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
revenue-growth
8.60%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AGEN VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AGEN | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 96.00% | 70.20% | +25.80 | AGEN | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 29.00% | -64.00 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -24.11% | 3.47% | -27.58 | ABBV | /fcf-yield <GO> |
| Operating Margin | -17.70% | 24.60% | -42.30 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -2.70% | 6.90% | -9.60 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 10.40% | 8.60% | +1.80 | AGEN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 5.33 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 7/9 | -4.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 46.7 | 65.1 | -18.38 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 113.1x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $320.2M | $513.86B | -$513.54B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AGEN REV | ABBV REV | AGEN GROSS % | ABBV GROSS % | AGEN FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $114.2M | $61.16B | 98.0% | 70.2% | -$77.2M | $17.82B |
| FY 2024 | $103.5M | $56.33B | 98.0% | 70.0% | -$158.9M | $17.83B |
| FY 2023 | $156.3M | $54.32B | — | — | -$224.2M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AGEN // BETA —
ABBV // BETA 1.15